Jan. 5, 2004 — Ann Arbor-based Velcura Therapeutics Inc. today was to announce the appointment of three new experts to the company's scientific advisory board. They are Julie Glowacki, Ph.D., professor in the department of orthopedic surgery and professor in the department of oral-maxillofacial surgery at the Harvard University school of medicine; John Lowe, M.D., professor in the department of pathology and Warner Lambert/Parke-Davis professor in the department of medicine at the University of Michigan; and W. Stratford May, M.D., Ph.D., director of the Shands Cancer Center and Harry F. Innes professor of cancer research at the University of Florida. The company is developing new and better ways to treat osteoporosis and other bone disorders. Glowacki's research examines the function of engineered joints, the molecular mechanism by which damaged bone initiates cartilage formation, and mechanisms by which steroid therapies increase bone mass. Lowe's work centers on the molecular control of protein modification events in inflammation and disease. May's research centers on protein signaling in cancer and other diseases.

Jan. 5, 2004 — ANN ARBOR, MICH., Jan. 5, 2004 – Michael W. Long, Ph.D., the President and CEO of Velcura Therapeutics™, Inc., recently announced that Julie Glowacki, Ph.D., John Lowe, M.D. and W. Stratford May, M.D., Ph.D. have joined the biotech company’s Scientific Advisory Board (SAB).

Nov. 19, 2003 — Ann Arbor-based Velcura Therapeutics Inc. Tuesday named Daniel Chagnovich as senior scientist in bioinformatics. Chagnovich most recently worked at Pfizer's global research and development center in Ann Arbor as a scientist in the molecular technologies group, where he spent two years in bioinformatics support for cardiovascular and proteomic research. He has extensive experience evaluating the human genome using bioinformatics tools, and has identified novel genes — one of which is in the patent application portfolio at Pfizer. Additionally, he developed bioinformatics tools to accelerate drug discovery that were used globally at Pfizer. Chagnovich earned his bachelor's degree in Biochemistry at the University of California, Riverside. He completed his Ph.D. in 1996 at Northwestern University Medical School in Chicago.

Nov. 18, 2003 — ANN ARBOR, MICH., Nov. 18, 2003 – Daniel Chagnovich, Ph.D. has joined Velcura Therapeutics™, Inc. as senior scientist, Bioinformatics. He most recently worked at Pfizer’s Global Research and Development Center in Ann Arbor as a scientist in the Molecular Technologies group.

Oct. 6, 2003 — ANN ARBOR, MICH., Oct. 6, 2003 –Velcura Therapeutics™, Inc. recently was awarded a $224,000 Phase 1 SBIR (Small Business Innovation Research) grant from the National Institute on Aging, National Institutes of Health (NIH).